ARCT
Price
$13.78
Change
-$0.70 (-4.83%)
Updated
Jul 11 closing price
Capitalization
373.72M
30 days until earnings call
BCLI
Price
$1.20
Change
-$0.02 (-1.64%)
Updated
Jul 11 closing price
Capitalization
11.81M
Interact to see
Advertisement

ARCT vs BCLI

Header iconARCT vs BCLI Comparison
Open Charts ARCT vs BCLIBanner chart's image
Arcturus Therapeutics Holdings
Price$13.78
Change-$0.70 (-4.83%)
Volume$251.25K
Capitalization373.72M
Brainstorm Cell Therapeutics
Price$1.20
Change-$0.02 (-1.64%)
Volume$251.8K
Capitalization11.81M
ARCT vs BCLI Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. BCLI commentary
Jul 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and BCLI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 13, 2025
Stock price -- (ARCT: $13.78 vs. BCLI: $1.20)
Brand notoriety: ARCT and BCLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 54% vs. BCLI: 14%
Market capitalization -- ARCT: $373.72M vs. BCLI: $11.81M
ARCT [@Biotechnology] is valued at $373.72M. BCLI’s [@Biotechnology] market capitalization is $11.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileBCLI’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • BCLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than BCLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 3 TA indicator(s) are bullish while BCLI’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 3 bullish, 5 bearish.
  • BCLI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BCLI is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а 0.00% price change this week, while BCLI (@Biotechnology) price change was +3.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.14%. For the same industry, the average monthly price growth was +16.46%, and the average quarterly price growth was +20.75%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

BCLI is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+9.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($374M) has a higher market cap than BCLI($11.8M). ARCT YTD gains are higher at: -18.798 vs. BCLI (-47.137). BCLI has higher annual earnings (EBITDA): -12.08M vs. ARCT (-63.92M). ARCT has more cash in the bank: 217M vs. BCLI (1.64M). BCLI has less debt than ARCT: BCLI (1.77M) vs ARCT (42.7M). ARCT has higher revenues than BCLI: ARCT (131M) vs BCLI (0).
ARCTBCLIARCT / BCLI
Capitalization374M11.8M3,169%
EBITDA-63.92M-12.08M529%
Gain YTD-18.798-47.13740%
P/E RatioN/AN/A-
Revenue131M0-
Total Cash217M1.64M13,200%
Total Debt42.7M1.77M2,412%
FUNDAMENTALS RATINGS
ARCT vs BCLI: Fundamental Ratings
ARCT
BCLI
OUTLOOK RATING
1..100
6971
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4961
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for BCLI (88) in the Computer Peripherals industry. This means that ARCT’s stock grew somewhat faster than BCLI’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

ARCT's Price Growth Rating (49) in the Pharmaceuticals Major industry is in the same range as BCLI (61) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTBCLI
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 23 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MAKOF3.900.13
+3.44%
Mako Mining Corp.
WRTBF22.35N/A
N/A
Wartsila Corp.
FMELF0.01N/A
N/A
FUTURE METALS NL
FPAFF0.74-0.01
-1.82%
First Pacific Company Ltd.
FRCOY29.62-2.03
-6.41%
Fast Retailing Co. Ltd.

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-4.83%
TRDA - ARCT
53%
Loosely correlated
-3.11%
RXRX - ARCT
52%
Loosely correlated
-7.61%
RGNX - ARCT
51%
Loosely correlated
-4.19%
ABCL - ARCT
51%
Loosely correlated
-5.65%
CRSP - ARCT
51%
Loosely correlated
-3.73%
More

BCLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCLI has been loosely correlated with VBIZF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCLI jumps, then VBIZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
-1.64%
VBIZF - BCLI
35%
Loosely correlated
N/A
ATHE - BCLI
35%
Loosely correlated
+17.99%
BLRX - BCLI
30%
Poorly correlated
-4.47%
XTLB - BCLI
29%
Poorly correlated
-0.66%
EYPT - BCLI
28%
Poorly correlated
-5.47%
More